Literature DB >> 32390227

Malignant pleural effusion survival prognostication in an Asian population.

Jonathan Caleb Quek1, Qiao Li Tan2, John Carson Allen1, Devanand Anantham1,2.   

Abstract

BACKGROUND AND
OBJECTIVE: LENT and PROMISE scores prognosticate survival in patients with MPE. Prognostication guides the selection of interventions and management. However, the predictive value of these scores and their refinements (modified-LENT) in Asians remain unclear. We aim to evaluate the performance of LENT, modified-LENT and clinical PROMISE scores; identify predictors of survival; and develop an alternative prognostication tool should current scores lack accuracy.
METHODS: Retrospective medical record review of an Asian pleuroscopy database from 2011 to 2018 of patients with MPE was conducted. The prognostic capability of current available scores were evaluated using C-statistics. Demographic and clinical variables as predictors of survival were assessed, and an alternative model was developed using logistic regression.
RESULTS: In 130 patients, the C-statistics for modified-LENT was not significantly different from LENT (0.59 (95% CI: 0.52-0.67) vs 0.56 (95% CI: 0.49-0.63); P = 0.403). In 57 patients, the PROMISE C-statistics was 0.72 (95% CI: 0.53-0.91). In our alternative prognostication model (n = 147), Sex, Eastern Cooperative Oncology Group status, Leukocyte count, EGFR mutation, Chemotherapy and primary Tumour type (SELECT) were predictors of 90-day mortality (C-statistic = 0.87 (95% CI: 0.79-0.95)). SELECT sensitivity, specificity, positive and negative predictive values, and positive and negative likelihood ratios using a predicted probability of 90-day mortality cut-off point of 10% were 0.91, 0.68, 0.34, 0.98, 2.83 and 0.13, respectively.
CONCLUSION: The LENT, modified-LENT and PROMISE scores have poor accuracy of survival prognostication in Asian patients with MPE undergoing pleuroscopy. The proposed SELECT prognostication model is accurate at identifying patients with high probability of survival at 90 days.
© 2020 Asian Pacific Society of Respirology.

Entities:  

Keywords:  cancer; malignant pleural effusion; mortality; prognosis; therapy

Mesh:

Year:  2020        PMID: 32390227     DOI: 10.1111/resp.13837

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  3 in total

Review 1.  Prognostic biomarkers of malignant patients with pleural effusion: a systematic review and meta-analysis.

Authors:  Peng Peng; Yuan Yang; Juan Du; Kan Zhai; Huan-Zhong Shi
Journal:  Cancer Cell Int       Date:  2022-02-24       Impact factor: 5.722

2.  Development and Validation of a Scoring System for Early Diagnosis of Malignant Pleural Effusion Based on a Nomogram.

Authors:  Aihua Wu; Zhigang Liang; Songbo Yuan; Shanshan Wang; Weidong Peng; Yijun Mo; Jing Yang; Yanqing Liu
Journal:  Front Oncol       Date:  2021-12-07       Impact factor: 6.244

3.  Pleural effusions associated with squamous cell lung carcinoma have a low diagnostic yield and a poor prognosis.

Authors:  Michael Dorry; Kevin Davidson; Rajesh Dash; Rachel Jug; Jeffrey M Clarke; Andrew B Nixon; Kamran Mahmood
Journal:  Transl Lung Cancer Res       Date:  2021-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.